Praxis Precision Medicines, Inc. (PRAX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$245.42

From 52W high−32.66%

Volume736319.00

Market cap$7.26B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$245.42

From 52W high

−32.66%

Volume

736319.00

Market cap

$7.26B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−19.2x

P/E (TTM)

—

RSI (14)

38.2

MomentumView details →

1D Return

+7.61%

YTD Return

−12.61%

SummaryUpdated Jun 1, 2026

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company founded in 2015 and based in Boston, Massachusetts. The company went public in October 2020 and specializes in developing precision therapies for central nervous system disorders characterized by neuronal imbalance. Praxis focuses on genetically-defined patient populations and employs a precision medicine approach to address conditions including essential tremor, epilepsy, and depression. The company currently operates multiple clinical programs across various stages of development, with several candidates approaching potential regulatory submissions.

Ask drillr about Praxis Precision Medicines, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−19.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

5.4x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−25.29%

ROA (TTM)

−24.40%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

−5.37%

FCF YoY

−60.10%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

−32.03%

EBITDA YoY

−29.90%

MomentumView details →

1D Return

+7.61%

YTD Return

−12.61%

1Y Return

+47.12%

RSI (14)

38.2

vs 50D SMA

−19.46%

vs 200D SMA

−18.37%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

15.73x

Quick Ratio

15.73x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$2.87

EPS Surprise

21.80%

Beats (12Q)

6/12

Next Q EPS Est

−$4.04

Avg Surprise (4Q)

4.59%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−339.13M

Op. CF (TTM)

−305.69M

Next earningsNov 9, 2026 →

Latest newsMore news →

Praxis Precision Medicines, Inc. shares hit a new 52-week high of $391.64 during mid-day trading on Tuesday, last trading at $376.38 with volume of 581,487 shares.63d ago

Praxis Precision Medicines is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, as both new drug applications remain under FDA review.74d ago

Similar companies

Alkermes plcALKS Ionis Pharmaceuticals, Inc.IONS 诺禾致源688315.SH 星湖科技600866.SH 苑东生物688513.SH Abivax S.A.ABVX Find similar companies →

Latest newsMore news →

Praxis Precision Medicines, Inc. shares hit a new 52-week high of $391.64 during mid-day trading on Tuesday, last trading at $376.38 with volume of 581,487 shares.63d ago Praxis Precision Medicines is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, as both new drug applications remain under FDA review.74d ago